Evidence map›Paper›PMID 36318182›Full record

ArticleLangmuir : the ACS journal of surfaces and colloids2022

Zonal Intratumoral Delivery of Nanoparticles Guided by Surface Functionalization.

Rossana Terracciano, Yareli Carcamo-Bahena, Amber Lee R Royal, Luca Messina, Jack Delk, E Brian Butler, Danilo Demarchi, Alessandro Grattoni, Zhihui Wang, Vittorio Cristini and 2 more

Open access · greenAbstract read
In one paragraph

Article in Langmuir : the ACS journal of surfaces and colloids, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Rossana TerraccianoDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, Texas77030, United States.ORCID 0000-0001-5026-0589
Yareli Carcamo-BahenaDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, Texas77030, United States.ORCID 0000-0001-9998-9696
Amber Lee R RoyalDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, Texas77030, United States.
Luca MessinaUnivestià degli Studi di Napoli Federico II, Naples80138, Italy.
Jack DelkTexas A&M University, College Station, Texas77843, United States.
E Brian ButlerDepartment of Radiation Oncology, Houston Methodist Research Institute, Houston, Texas77030, United States.
Danilo DemarchiDepartment of Electronics and Telecommunications, Politecnico di Torino, Torino10129, Italy.
Alessandro GrattoniDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, Texas77030, United States.ORCID 0000-0001-7888-422X
Zhihui WangMathematics in Medicine Program, Houston Methodist Research Institute, Houston, Texas77030, United States.ORCID 0000-0001-6262-700X
Vittorio CristiniMathematics in Medicine Program, Houston Methodist Research Institute, Houston, Texas77030, United States.
Prashant DograMathematics in Medicine Program, Houston Methodist Research Institute, Houston, Texas77030, United States.
Carly S FilgueiraDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, Texas77030, United States.ORCID 0000-0002-3246-303X
Houston Methodist · USPolitecnico di Torino · ITTexas A&M University · USUniversity of Naples Federico II · IT

Funding

A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate CancerR01CA226537 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI ARAP, WADIH, BRINKER, C JEFFREY · 2018 to 2022
$3.2M
miR-155 targeted therapeutics for precision medicine in lung cancerR01CA222007 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CALIN, GEORGE A., CRISTINI, VITTORIO · 2018 to 2022
$2.6M
Nanoparticle delivery of miRNA-based therapeutics to overcome clinical challenges in triple negative breast cancerR01CA253865 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI OZPOLAT, BULENT, WANG, ZHIHUI · 2021 to 2025
$2.0M
NCI NIH HHS R01 CA222007NCI NIH HHS R01 CA226537NCI NIH HHS R01 CA253865
6 · The paper itself

Abstract

Delivery of small molecules and anticancer agents to malignant cells or specific regions within a tumor is limited by penetration depth and poor spatial drug distribution, hindering anticancer efficacy. Herein, we demonstrate control over gold nanoparticle (GNP) penetration and spatial distribution across solid tumors by administering GNPs with different surface chemistries at a constant injection rate via syringe pump. A key finding in this study is the discovery of different zone-specific accumulation patterns of intratumorally injected nanoparticles dependent on surface functionalization. Computed tomography (CT) imaging performed in vivo of C57BL/6 mice harboring Lewis lung carcinoma (LLC) tumors on their flank and gross visualization of excised tumors consistently revealed that intratumorally administered citrate-GNPs accumulate in particle clusters in central areas of the tumor, while GNPs functionalized with thiolated phosphothioethanol (PTE-GNPs) and thiolated polyethylene glycol (PEG-GNPs) regularly accumulate in the tumor periphery. Further, PEG functionalization resulted in larger tumoral surface coverage than PTE, reaching beyond the outer zone of the tumor mass and into the surrounding stroma. To understand the dissimilarities in spatiotemporal evolution across the different GNP surface chemistries, we modeled their intratumoral transport with reaction-diffusion equations. Our results suggest that GNP surface passivation affects nanoparticle reactivity with the tumor microenvironment, leading to differential transport behavior across tumor zones. The present study provides a mechanistic understanding of the factors affecting spatiotemporal distribution of nanoparticles in the tumor. Our proof of concept of zonal delivery within the tumor may prove useful for directing anticancer therapies to regions of biomarker overexpression.

Indexed as

Metal NanoparticlesNanoparticlesAnimalsCitric AcidGoldMiceMice, Inbred C57BLPolyethylene GlycolsCitric AcidGoldPolyethylene Glycols

Identifiers

PMID36318182
PMCPMC9671122
OpenAlexW4307794031

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.